# Tirzepatide

Mounjaro · Zepbound · LY3298176

https://graded.pl/en/substances/tirzepatide · Checked: Not yet

Preliminary version. The editors have not finished checking this card, and grades may change.

A medicine that mimics two gut hormones, GIP and GLP-1, which affect appetite and blood sugar. Approved in the EU and US for type 2 diabetes and obesity. Approval covers only these medicines.

> This site is for information and education only. It does not promote or encourage the use or purchase of the substances described and is not medical advice. Many are not authorised as medicines and their safety has not been established. We sell nothing and have no ties to sellers. For health decisions, consult a doctor.

## Short answers

### Does tirzepatide work?

A medicine that mimics two gut hormones, GIP and GLP-1, which affect appetite and blood sugar. Approved in the EU and US for type 2 diabetes and obesity. Approval covers only these medicines. Fat loss: grade A, effect in studies. Weight fell by 20.9% on average at the highest dose studied, and by 3.1% on placebo, after 72 weeks. In people with diabetes it fell 12.8% to 14.7%, and 3.2% on placebo. Weight came back after stopping. The maker paid for the studies, which tested the pharmacy medicine.

### Is Tirzepatide legal?

PL: Prescription only. The EU-wide approval of Mounjaro covers Poland. The European medicines database (EMA) shows no separate Polish product (9 October 2026). EU: Prescription only. Approved across the EU as Mounjaro. This covers that medicine only, not products sold outside pharmacies. US: Prescription only. Prescription medicine (Mounjaro).

### Is tirzepatide banned in sport?

Allowed, being watched, WADA 2026. Not banned. In 2026 WADA is collecting data on its use in sport.

### Is Tirzepatide safe?

Well known. Large studies and a US drug label. The label carries its strongest warning, on rare thyroid tumours in rats, and lists severe stomach and bowel problems. This describes the pharmacy medicine.

## What studies show

| | | | |
|---|---|---|---|
| Fat loss | A | Effect in studies | Weight fell by 20.9% on average at the highest dose studied, and by 3.1% on placebo, after 72 weeks. In people with diabetes it fell 12.8% to 14.7%, and 3.2% on placebo. Weight came back after stopping. The maker paid for the studies, which tested the pharmacy medicine. |

## Studies we have read

- Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. (JAMA 2024; Random groups, n=670) https://pubmed.ncbi.nlm.nih.gov/38078870/
- Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. (Lancet (London, England) 2023; Random groups) https://pubmed.ncbi.nlm.nih.gov/37385275/
- Tirzepatide Once Weekly for the Treatment of Obesity. (The New England journal of medicine 2022; Random groups, n=2539) https://pubmed.ncbi.nlm.nih.gov/35658024/

## Is it legal

- PL: Prescription only. The EU-wide approval of Mounjaro covers Poland. The European medicines database (EMA) shows no separate Polish product (9 October 2026). https://www.ema.europa.eu/en/documents/other/article-57-product-data_en.xlsx (Checked: Not yet)
- EU: Prescription only. Approved across the EU as Mounjaro. This covers that medicine only, not products sold outside pharmacies. https://www.ema.europa.eu/en/medicines/human/EPAR/mounjaro (Checked: Not yet)
- US: Prescription only. Prescription medicine (Mounjaro). https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=215866 (Checked: Not yet)

## Doping

Allowed, being watched, WADA 2026. https://www.gov.br/abcd/pt-br/composicao/atletas/substancias-e-metodos-proibidos/2026ProgramadeMonitoramento.pdf

## How much research exists

- Scientific papers: 2711
- Studies with random groups: 135
- Registered studies in people: 309
- These are search results. A count shows how much exists, not how good the studies are. 1 Nov 2026.

---
Open data: CC BY 4.0, https://creativecommons.org/licenses/by/4.0/